Skorney, based in New York City, initiated coverage on four biotech companies including Achillion Pharmaceuticals Inc. (ACHN), Cubist Pharmaceuticals, Inc. (CBST), Gilead Sciences, Inc. (GILD) and InterMune, Inc. (ITMN).
'Brian’s sector knowledge is a valuable complement to Baird’s already successful Biotechnology coverage', said Jon Langenfeld, Director of Equity Research. 'Brian’s addition extends our underlying commitment to our Equity Capital Markets Healthcare franchise'.
In addition to the firm’s broad Healthcare/Life Science research investment, Baird has a full complement of Capital Markets, Sales, Trading and Strategic Advisory Healthcare specialists proving comprehensive worldwide investment banking services to all segments of the healthcare industry.
Brian Skorney, CFA Biography
Brian Skorney is one of Baird’s senior analysts covering Biotechnology. Skorney has followed the sector for six years, most recently at Brean Murray Carret & Co. Prior to his career in equity research, Skorney worked in medical research. Skorney received a B.S. in Biological Sciences from The University of Notre Dame and an MBA in Finance from The Stern School of Business at New York University.
About Baird’s Equity Research Team
Baird’s Equity Research Department consists of over 120 research professionals covering more than 690 companies. Baird analysts have been recognized repeatedly in The Wall Street Journal’s annual “Best on the Street” survey and inStarMine’s annual top analyst rankings.
In 2012, Baird was awarded a No. 1 ranking by Greenwich Associates for U.S. Small- and Mid-Cap Equities for Most Trusted Research, Analyst Service and Sales Quality. The April 2012 Greenwich Associates U.S. Equity Investors-Small/Mid-Cap Funds survey was conducted with 94 U.S. small-cap and mid-cap fund managers. Rankings were based on the top ten research firms in the survey.